10-Q: Scientist Home Future Health Q1 2026 Results Show Significant Revenue Growth

Scientist Home Future Health Limited reported a substantial increase in revenue for the first quarter of 2026, driven by its retail trading segment, though the company continues to face challenges with profitability and liquidity.

Summary

• Scientist Home Future Health Limited reported total revenues of $188,756 for the three months ended March 31, 2026, a significant increase from $44,824 in the same period of 2025.
• The primary revenue driver was the retail trading of health supplements and topical creams, which generated $182,278, with the remaining $6,478 from physical check-up services.
• Cost of revenues for the period was $129,688, leading to a gross profit of $59,068.
• Selling, general, and administrative expenses increased significantly to $161,140 in Q1 2026 from $12,695 in Q1 2025.
• The company reported a net loss of $102,072 for the three months ended March 31, 2026, compared to a net income of $6,059 for the same period in 2025.
• Cash and cash equivalents decreased from $68,888 at the end of 2025 to $15,332 at the end of Q1 2026.
• The company has net current liabilities of $120,220 as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern.
• Net cash used in operating activities was $71,811 for Q1 2026, compared to $4,832 for Q1 2025.
• Financing activities provided $18,510 in net cash for Q1 2026, primarily from advances from related parties and a director.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant net loss, increased operating expenses, declining cash reserves, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern.

Positives

• Significant year-over-year revenue growth, with total revenues increasing from $44,824 in Q1 2025 to $188,756 in Q1 2026.
• Retail trading revenue, the main revenue stream, saw substantial growth, indicating increasing customer demand for health supplements and topical creams.
• The company has no customers accounting for more than 10% of its total revenue, indicating a diversified customer base.
• The company has no significant off-balance sheet arrangements.

Negatives

• A substantial net loss of $102,072 was incurred in Q1 2026, a reversal from a net income of $6,059 in Q1 2025.
• Selling, general, and administrative expenses increased dramatically by over 1100% to $161,140 in Q1 2026 from $12,695 in Q1 2025.
• Cash and cash equivalents significantly decreased to $15,332 from $68,888.
• The company has net current liabilities of $120,220, raising substantial doubt about its ability to continue as a going concern.
• Net cash used in operating activities increased substantially to $71,811 from $4,832.
• The company's independent auditors expressed substantial doubt about its ability to continue as a going concern.
• The company has material weaknesses in its internal control over financial reporting, including insufficient segregation of duties, lack of an independent board of directors or audit committee, and no written documentation of internal control policies and procedures.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern within one year due to net losses and net current liabilities.
• The company's ability to continue as a going concern is dependent on improving profitability and securing continuing financial support from major shareholders or external financing, with no assurance of availability or favorable terms.
• Potential for dilution to shareholders if future financing is equity-based.
• Potential for undue restrictions on operations if future financing is debt-based.
• The company relies on a single vendor for 100% of its cost of revenues, creating significant supply chain risk.
• The company has limited management and resources, and lacks an independent board of directors or audit committee, which are identified as material weaknesses in internal controls.

Future Outlook

The company's ability to continue as a going concern is dependent on improving its profitability and securing continuing financial support from its major shareholders or external financing. Management believes that existing shareholders or external financing will provide additional cash to meet obligations, but there is no assurance that future financing will be available or on satisfactory terms.

Management Comments

• The company's mission is to develop sustainable rehabilitation solutions, particularly for degenerative diseases, ensuring that our products not only address current symptoms but also support future, long-term health and recovery.
• We believe that Scientist Home Future Health Limited is more than just a company - its a movement towards better health, driven by innovation, tradition, and a deep respect for the healing power of nature.
• As we continue to expand our reach, our vision remains clear: to be a leading force in the health and wellness industry.

Industry Context

StockSavvy.ai notes that Scientist Home Future Health Limited operates in the health supplements and topical creams market, alongside providing physical check-up services. This sector is generally characterized by growing consumer interest in wellness and preventative healthcare. However, the company's significant increase in SG&A expenses and net loss, coupled with going concern issues, suggest operational challenges that may be exacerbated in a competitive market where established players often have greater economies of scale and brand recognition.

Comparison to Industry Standards

• The company's revenue growth is positive, but its significant increase in operating expenses and resulting net loss are concerning when compared to industry standards for profitability in the health and wellness sector.
• Many companies in the health and wellness sector aim for positive net income and healthy cash flow from operations. Scientist Home Future Health's current financial state, with a net loss and negative operating cash flow, deviates significantly from these standards.
• The reliance on a single vendor for 100% of cost of revenues is a critical operational risk not typically seen in well-established industry players who diversify their supply chains.
• The identification of material weaknesses in internal controls is a significant concern, as robust internal controls are a fundamental expectation for publicly traded companies across all industries.

Corporate Governance

Legal Proceedings

• The company's officers and directors are not aware of any threatened or pending litigation that would have a material, adverse effect on the company.

Related Party Transactions

• The company rents office spaces from Related party A (an entity owned by the CEO) for $1,280/month (July 2024-June 2025) and $1,920/month (July 2025-June 2027).
• The company purchases trading goods and courier services from Related party B (an entity owned by the CEO), amounting to $127,296 for the period ended March 31, 2026.
• As of March 31, 2026, the amount due to Related party B operating was $110,610, of which $47,295 is trade-related and $63,315 is non-trade related and repayable on demand.
• Cost of retail trading revenue includes $129,688 to a related party (Vendor A, owned by the CEO) for the period ended March 31, 2026.
• Selling, general, and administrative expenses include $5,760 to a related party for the period ended March 31, 2026.

Stakeholder Impact

• Shareholders: Potential for significant dilution if future financing is equity-based; current financial performance and going concern issues pose a risk to investment value.
• Creditors: The company's net current liabilities and going concern issues may impact its ability to meet short-term obligations.
• Employees: Increased SG&A expenses could indicate growth or investment in personnel, but the overall financial instability may create job security concerns.
• Suppliers: The company's reliance on a single vendor for 100% of its cost of revenues creates a risk for that vendor if the company's financial situation deteriorates.

Next Steps

• Implement an independent board of directors.
• Establish written policies and procedures for internal control of financial reporting.
• Hire additional accounting personnel at such time as a reverse merger or similar business acquisition is completed.

Key Dates

Recommendation

The company's Q1 2026 results show a significant deterioration in financial performance, marked by a substantial net loss, a dramatic increase in operating expenses, and a sharp decline in cash reserves. The explicit statement of substantial doubt regarding the company's ability to continue as a going concern, coupled with identified material weaknesses in internal controls, presents a high level of risk for investors. While revenue has grown, it has not translated into profitability, and the operational and financial instability suggests a high probability of further value erosion.

Keywords

Scientist Home Future Health, 10-Q, Quarterly Report, Financial Statements, Revenue, Net Loss, Going Concern, Health Supplements, Topical Creams, Physical Check-up Services, Hong Kong